You are here

Pfizer

ASCO: Pfizer, Astellas' Xtandi racks up more data for new prostate cancer approval

Fierce Pharma

Sun, 06/2/19 - 01:17 pm

prostate cancer

Pfizer's new Vyndaqel franchise worth far more than $1.5B, analyst figures

Fierce Pharma

Thu, 05/30/19 - 12:36 pm

Verily lures major pharmas with promise of speedier clinical research

BioPharma Dive

Tue, 05/21/19 - 11:07 pm

clinical trials

Where Will Pfizer Be in 5 Years?

Motley Fool

Sat, 05/18/19 - 08:49 pm

EMA imposes formal limit on Xeljanz prescription as regulators continue to review safety concerns

Endpoints

Sat, 05/18/19 - 08:47 pm

post-marketing studies

Pfizer’s blood clot drug Fragmin gets FDA approval for pediatric patients

Pharmaceutical Business Review

Fri, 05/17/19 - 09:57 am

Pfizer’s Abrocitinib yields positive results in phase 3 moderate to severe AD trial

Pharmaceutical Business Review

Thu, 05/16/19 - 10:55 am

clinical trials

atopic dermatitis

Merck and Pfizer’s Bavencio approved for renal cell carcinoma

Pharmaforum

Wed, 05/15/19 - 10:35 am

advanced renal cell carcinoma

Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large

Endpoints

Wed, 05/15/19 - 10:24 am

anti-inflammatories

Pfizer selects first GPCR candidate from Sosei Heptares tie-up

Pharmaforum

Tue, 05/14/19 - 09:53 am

drug development

[video]Top vaccine makers Merck and Pfizer target China and older adults next

Yahoo/CNBC

Sun, 05/12/19 - 01:25 pm

How Viagra revolutionized the erectile dysfunction market

CNBC

Sat, 05/11/19 - 12:15 pm

erectile dysfunction

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

BioCentury

Sat, 05/11/19 - 12:12 pm

Looking to topple Pfizer's Prevnar 13 dynasty, Merck claims another win for its 'breakthrough' pneumococcal conjugate vaccine

Endpoints

Wed, 05/8/19 - 12:30 pm

pneumococcal disease

Pfizer agrees on $340M upfront to buy Therachon for dwarfism drug

Fierce Biotech

Wed, 05/8/19 - 10:42 am

short-limbed dwarfism

Can Pfizer Leap Over the Competition With This Potential Blockbuster?

Motley Fool

Wed, 05/8/19 - 10:03 am

Akcea Therapeutics

Eidos Therapeutics

Pfizer Calls for Compromise on Retroactively Using Suffixes in Biologic Names

RAPS.org

Tue, 05/7/19 - 06:47 pm

Insurers Brace For Pfizer's $225K Heart Drug And Whether To Pay For It

Forbes

Mon, 05/6/19 - 07:27 pm

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

Xconomy

Mon, 05/6/19 - 10:54 am

ED Drug Shows Promise in Sheep Heart Failure Study

BioSpace

Mon, 05/6/19 - 10:48 am

Pages